Agilent Technologies: Philip Binns

Sep 05, 2023

Agilent Technologies has named Philip Binns as president of its Life Sciences and Applied Markets group. He previously served as VP and general manager of the LSAG's spectroscopy and vacuum solutions division and replaces Jacob Thaysen, who recently left Agilent to become CEO of Illumina. Binns joined Agilent in 2010 through its acquisition of Varian.

Breaking News

FDA Grants Emergency Use Authorizations for POC COVID Tests from Tangen Biosciences, SD Biosensor
Top Five Articles on GenomeWeb Last Week: FDA Proposal for LDT Oversight, Adela $48M Financing, More
FDA Grants Marketing Authorization for Invitae Hereditary Cancer DNA Sequencing Test
Compact Gene Editing Enzyme May Improve Success Rates of Gene Therapies
People in the News at Veracyte, Invitae, Mount Sinai, InterVenn Biosciences, Applied BioCode, More

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.